Welcome to our dedicated page for Cybin SEC filings (Ticker: HELP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Cybin's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Cybin's regulatory disclosures and financial reporting.
Tang Capital Management and related entities have exited their stake in Cybin Inc. In Amendment No. 3 to a Schedule 13G, Tang Capital Management, Kevin Tang, and affiliated partnerships and corporations report beneficial ownership of 0 shares of Cybin common stock, or 0% of the class, as of December 31, 2025.
The filing confirms they no longer have sole or shared voting or dispositive power over any Cybin shares and state that the securities were not acquired or held to change or influence control of the company.
Deep Track Capital and affiliated entities report owning 2,391,505 Cybin Inc. common shares, representing 4.74% of the class as of December 31, 2025. The position includes 537,250 warrants exercisable into common stock, subject to a 9.99% maximum beneficial ownership limitation.
The ownership calculation uses 50,431,381 shares, based on 49,894,131 common shares outstanding as of December 19, 2025 plus the warrants counted up to the stated cap. The filers certify the holdings are not for the purpose of changing or influencing control of Cybin.
Helus Pharma, formerly Cybin Inc., reported a larger loss but a much stronger balance sheet for the three and nine months ended December 31, 2025. The company, a clinical-stage pharmaceutical developer of novel serotonergic agonists, posted a nine‑month net loss of $101,003 compared with $60,300 a year earlier, driven mainly by higher research spending of $57,702 and general and administrative costs of $31,419.
Despite the wider loss, liquidity improved significantly. Cash increased to $195,128 from $93,922 as of March 31, 2025, supported by net financing inflows of $198,408, including a registered direct offering of 22,277,750 common shares and 4,605,500 pre‑funded warrants with gross proceeds of about $175,010, and an earlier at‑the‑market program raising $10,465. Total assets rose to $290,112 and shareholders’ equity to $273,934, while the accumulated deficit reached $342,540.
The company issued and then fully extinguished $50,000 of unsecured convertible debentures during the period, recognizing a fair value loss of $5,500 before repaying the remaining principal and fees. It also expanded equity‑based incentives, with 4,169,617 stock options, 12,205,335 warrants, 4,605,500 pre‑funded warrants and 4,164,440 restricted share units outstanding at December 31, 2025. Helus Pharma subsequently moved its U.S. listing to Nasdaq under the symbol “HELP” and notes clinical and commercial commitments, including up to $109,950 for contracted studies and milestone obligations of up to $9,500 under a license agreement, alongside ongoing development of its HLP003, HLP004 and HLP005 programs.
Cybin Inc.’s commercial operating unit Helus Pharma has appointed industry veteran Michael Cola as Chief Executive Officer, effective immediately. He brings more than 30 years of experience in neuroscience, rare disease and specialty pharmaceuticals, including leading Shire’s Specialty Pharmaceutical business and senior roles at Astra-Merck and AstraZeneca.
Helus is advancing a pipeline of novel serotonergic agonists for serious mental health disorders, with Phase 2 data for HLP004 expected in the first quarter of 2026 and Phase 3 topline data for HLP003 expected in the fourth quarter of 2026. The company has filed more than 350 patent applications globally and has been granted over 100 patents as it moves from early clinical development toward later-stage execution, global regulatory engagement and long-term commercial planning.